sepsi
lead
caus
mortal
patient
haematolog
malign
solid
tumour
undergo
intens
cytotox
chemotherapi
therefor
optim
diagnosi
manag
sepsi
could
improv
outcom
intens
cytotox
therapi
number
prior
guidelin
manag
sepsi
publish
howev
none
guidelin
specif
address
diagnosi
manag
sepsi
neutropen
patient
updat
guidelin
written
provid
guidanc
diagnosi
manag
sepsi
neutropen
host
first
panel
expert
field
infecti
diseas
haematolog
oncolog
agre
particip
prepar
guidelin
second
guidelin
themat
divid
six
subtop
subcommitte
two
four
author
creat
respons
literatur
search
one
subtop
systemat
search
medlin
english
languag
public
june
use
key
term
sepsi
one
follow
neutropenia
bacteraemia
bloodstream
infect
bacteraemia
definit
epidemiolog
incid
risk
factor
prognosi
treatment
antibiot
antifung
cardiovascular
pulmonari
failur
ventil
renal
dysfunct
renal
failur
dialysi
haemofiltr
nutrit
hyperglycaemia
steroid
coagul
growth
factor
immunoglobulin
transfus
meet
abstract
includ
howev
refer
gener
publish
guidelin
review
also
investig
consensu
process
perform
email
meetingbas
discuss
group
second
step
manuscript
draft
peer
review
review
committe
infecti
diseas
work
parti
german
societi
hematolog
medic
oncolog
agiho
octob
third
step
guidelin
approv
assembl
member
octob
criteria
use
quot
level
grade
evid
outlin
tabl
first
draft
manuscript
written
subcommitte
final
version
manuscript
prepar
correspond
author
approv
author
formal
definit
sepsi
long
tri
sever
research
must
lack
specif
given
broad
spectrum
reaction
pathogen
suggest
use
diagnost
consensu
criteria
sepsi
adapt
neutropen
patient
tabl
neutropen
patient
white
blood
cell
count
use
criterion
defin
sepsi
definit
sever
sepsi
septic
shock
remain
unchang
refer
sepsisinduc
organ
dysfunct
tabl
systemat
data
evalu
overal
incid
neutropen
sepsi
cancer
patient
lack
incid
febril
neutropenia
bacteraemia
studi
detail
albeit
major
studi
use
uniform
definit
includ
least
partli
nonneutropen
patient
focu
distinct
patient
subgroup
patient
solid
tumour
develop
febril
neutropenia
around
complic
might
occur
patient
haematolog
malign
patient
indwel
central
venou
cathet
cvc
febril
neutropenia
frequent
caus
catheterrel
catheterassoci
bacteraemia
incid
around
neutropen
day
likewis
transloc
gut
organ
vancomycinresist
enterococci
vre
may
caus
bacteraemia
ultim
sepsi
neutropen
cancer
patient
colon
patient
assum
patient
febril
neutropenia
bacteraemia
develop
sepsi
use
consensu
definit
sever
sepsi
septic
shock
investig
prospect
retrospect
analys
might
occur
patient
febril
neutropenia
respect
increas
number
elderli
patient
undergo
intens
treatment
modal
patient
infect
treatmentresist
organ
led
assumpt
frequenc
neutropen
sepsi
increas
data
risk
factor
bacteraemia
neutropenia
apostolopoul
et
al
observ
signific
higher
rate
bacteraemia
potenti
result
sepsi
patient
neutropenia
gl
addit
acut
myeloid
leukaemia
prolong
hospit
stay
hickman
cathet
pretreat
antibiot
chemotherapi
surgeri
significantli
associ
bsi
haematolog
oncolog
patient
presenc
hypophosphataemia
mmoll
hypoproteinaemia
gl
identifi
risk
factor
sever
sepsi
febril
neutropenia
develop
septic
shock
febril
neutropenia
independ
predict
presenc
pulmonari
infect
tachypnoea
increas
serum
level
procalcitonin
ngml
high
lactat
level
decreas
serum
level
bicarbon
mmoll
antithrombin
factor
viia
ngml
low
multin
associ
support
care
cancer
mascc
risk
index
score
associ
increas
risk
septic
shock
febril
neutropen
patient
prolong
neutropenia
gl
delay
initi
antibiot
associ
poor
clinic
outcom
neutropen
patient
sepsi
sever
sepsi
septic
shock
neg
influenc
outcom
recent
prospect
studi
demonstr
mortal
rate
sever
sepsi
septic
shock
multiorgan
failur
patient
haematolog
malign
factor
significantli
associ
hospit
surviv
includ
remiss
malign
tumour
time
intens
care
unit
icu
admiss
h
neg
predict
factor
hospit
surviv
follow
allogen
haemopoiet
stem
cell
transplant
hsct
poor
perform
statu
invas
pulmonari
aspergillosi
malign
organ
infiltr
acut
respiratori
failur
anoth
studi
legrand
et
al
identifi
prognost
factor
neutropen
patient
sever
sepsi
septic
shock
appear
acut
noninfecti
complic
neurolog
respiratori
hepat
dysfunct
need
vasopressor
therapi
older
age
increas
mortal
hand
earli
remov
cvc
combin
antibiot
therapi
associ
higher
surviv
blood
cultur
part
usual
microbiolog
workup
per
local
protocol
includ
urin
cultur
stool
cultur
etc
remain
gold
standard
diagnosi
bacteraemia
fungaemia
blood
cultur
standard
term
volum
cultur
set
frequenc
process
interpret
report
howev
although
episod
febril
neutropenia
assum
caus
infect
blood
cultur
posit
less
febril
neutropen
episod
typic
organ
caus
sepsi
neutropenia
summar
tabl
epidemiolog
gramposit
versu
gramneg
bacteraemia
vari
differ
countri
contrast
countri
germani
predomin
gramposit
bacteria
caus
febril
neutropenia
knowledg
local
epidemiolog
essenti
ration
choic
empir
antibiot
therapi
alreadi
point
other
particularli
true
colon
resist
bacteria
sinc
associ
increas
risk
bacteraemia
pathogen
pcrbase
method
detect
bacteri
fungal
dna
yet
valid
larger
cohort
contrast
pcrbase
method
play
definit
role
diagnosi
viral
infect
may
caus
sepsi
sever
immunocompromis
patient
empir
antimicrobi
treatment
use
broadspectrum
antibiot
must
start
immedi
neutropen
patient
sepsi
aii
larg
retrospect
studi
includ
patient
show
sever
sepsi
effect
antimicrobi
administr
within
first
hour
document
hypotens
associ
increas
surviv
studi
hour
delay
antimicrobi
administr
ensu
h
associ
averag
decreas
surviv
neutropen
patient
sepsi
result
random
control
trial
lack
recommend
base
studi
result
nonneutropen
patient
well
expert
opinion
recommend
initi
treatment
meropenem
imipenemcilastatin
piperacillintazobactam
aiii
metaanalys
show
combin
treatment
aminoglycosid
increas
renal
toxic
without
improv
efficaci
neutropen
patient
bacteraemia
howev
retrospect
studi
use
antibioticaminoglycosid
combin
associ
superior
outcom
compar
singleag
antimicrobi
treatment
neutropen
patient
sever
sepsi
septic
shock
anoth
retrospect
studi
show
reduc
hospit
mortal
nonneutropen
patient
sever
bacteri
sepsi
combin
therapi
compris
least
two
antibiot
differ
mechan
versu
antibiot
monotherapi
taken
togeth
combin
treatment
aminoglycosid
may
consid
neutropen
patient
septic
shock
sever
sepsi
biii
knowledg
local
microbiolog
data
crucial
choic
antimicrobi
agent
importantli
local
resist
pattern
well
colon
resist
bacteria
consid
infect
due
bacteria
frequent
resist
carbapenem
piperacillintazobactam
suspect
specif
antibiot
ad
biii
specif
organ
infect
suspect
antibiot
therapi
adapt
accordingli
recommend
antifung
therapi
neutropenia
recent
publish
group
other
aggress
earli
goaldirect
treatment
aim
restor
cardiovascular
function
crucial
restor
adequ
cardiac
fill
pressur
maintain
adequ
organ
perfus
goal
mean
arteri
pressur
mmhg
central
venou
pressur
mmhg
pulmonari
wedg
pressur
mmhg
urinari
output
mlkgh
central
venou
mix
venou
oxygen
satur
crystalloid
fluid
recommend
initi
fluid
choic
sever
sepsi
septic
shock
compar
crystalloid
random
control
trial
show
benefici
effect
colloid
especi
hydroxyethyl
starch
fluid
resuscit
sepsi
howev
risk
acut
kidney
injuri
requir
renal
replac
therapi
substanti
increas
use
hydroxyethyl
starch
ei
larg
random
studi
indic
albumin
administr
safe
equal
effect
salin
metaanalysi
data
random
trial
found
use
albumincontain
solut
fluid
resuscit
patient
sepsi
associ
lower
mortal
compar
crystalloid
howev
multicent
random
trial
n
patient
septic
shock
use
albumin
therapi
significantli
reduc
mortal
compar
salin
solut
thu
albumincontain
solut
may
use
fluid
resuscit
patient
sepsi
septic
shock
cii
suffici
mean
arteri
pressur
mmhg
achiev
volum
substitut
reason
time
frame
treatment
vasopressor
indic
drug
choic
elev
vasotonu
norepinephrin
dose
bii
retrospect
small
prospect
studi
vasopressin
umin
increas
urinari
output
creatinin
clearanc
compar
norepinephrin
howev
larg
vasst
trial
reduct
mortal
found
vasopressin
group
current
poor
evid
support
use
vasopressin
septic
shock
ci
case
sepsisrel
myocardi
depress
lead
low
cardiac
output
despit
adequ
volum
substitut
vasopressor
treatment
dobutamin
institut
aii
note
result
observ
studi
suggest
dopamin
administr
may
associ
increas
mortal
rate
septic
patient
bicarbon
therapi
recommend
purpos
improv
haemodynam
reduc
vasopressor
requir
presenc
lactic
acidosi
ph
dii
pneumonia
lead
acut
respiratori
failur
major
caus
sepsi
neutropen
cancer
patient
hand
sever
sepsi
may
lead
acut
lung
injuryacut
respiratori
distress
syndrom
ard
cooper
awak
patient
mild
moder
pulmonari
failur
noninvas
posit
pressur
ventil
prefer
aii
noninvas
treatment
option
led
signific
reduct
intub
compar
control
group
neutropen
cancer
patient
earli
start
noninvas
ventil
prior
develop
sever
hypoxaemia
favour
bii
failur
noninvas
ventil
occur
half
critic
ill
haematolog
patient
associ
increas
mortal
predictor
noninvas
ventil
failur
follow
high
respiratori
rate
short
time
admiss
noninvas
ventil
vasopressor
use
renal
replac
therapi
develop
ard
moder
sever
respiratori
insuffici
endotrach
intub
mechan
ventil
necessari
surviv
posit
correl
experi
icu
haematolog
oncolog
patient
retrospect
multicent
studi
allogen
hsct
recipi
admit
icu
mechan
ventil
associ
low
surviv
rate
data
confirm
prospect
studi
percutan
extracorpor
membran
oxygen
show
rescu
therapi
bridg
hypoxemia
due
ard
patient
oncolog
malign
haematolog
diseas
studi
need
field
recommend
given
acut
kidney
injuri
aki
develop
approxim
patient
sever
sepsi
septic
shock
combin
acut
renal
failur
sepsi
associ
mortal
specif
data
neutropen
patient
lack
recommend
manag
renal
dysfunct
differ
nonneutropen
patient
short
clear
guidelin
time
initi
renal
replac
therapi
rrt
given
regard
mode
replac
therapi
intermitt
haemodialysi
continu
renal
replac
therapi
crrt
equival
patient
sepsi
aki
bi
haemodynam
unstabl
patient
control
fluid
balanc
may
facilit
use
crrt
bii
increas
frequenc
rrt
thought
reduc
rate
urem
complic
improv
outcom
patient
aki
howev
random
control
studi
show
conflict
result
recent
metaanalysi
indic
highdos
rrt
critic
ill
patient
aki
improv
patient
surviv
recoveri
renal
function
compar
lessintens
regim
thu
firm
recommend
given
increas
frequenc
rrt
ci
patient
undergo
renal
replac
therapi
dosag
antimicrobi
substanc
care
check
adjust
use
lowdos
dopamin
protect
renal
function
recommend
ei
recommend
report
extrapol
analys
critic
ill
wellnourish
patient
without
neutropenia
enter
nutrit
prefer
parenter
nutrit
unless
contraind
imposs
associ
lower
rate
infect
bii
enter
calor
intak
calcul
accord
phase
sepsi
initi
phase
sepsi
suppli
kcalkg
ideal
bodyweight
ibw
associ
inferior
outcom
one
observ
studi
diii
recoveri
kcalkg
ibw
provid
biii
reproduc
mortal
benefit
supplement
arginin
fatti
acid
combin
formul
patient
sever
sepsi
septic
shock
lack
recommend
gener
use
either
supplement
dii
substitut
glutamin
posit
affect
primari
surviv
endpoint
two
random
trial
includ
togeth
patient
sepsi
significantli
increas
inhospit
mortal
redox
studi
therefor
glutamin
substitut
recommend
ei
two
recent
larg
random
twofactori
trial
compar
influenc
lower
dose
selenium
substitut
placebo
critic
ill
patient
trial
includ
septic
patient
respect
selenium
substitut
effect
mortal
smaller
trial
higher
dose
selenium
substitut
daili
associ
mortal
reduct
per
protocol
analysi
metaanalysi
includ
nine
trial
septic
patient
selenium
substitut
associ
lower
mortal
especi
patient
receiv
selenium
higher
dose
mg
daili
day
thu
clinic
trial
regard
adequ
dose
treatment
durat
need
treatment
selenium
recommend
di
hyperglycaemia
patient
requir
intens
care
associ
inferior
outcom
result
clinic
trial
patient
sever
sepsi
septic
shock
well
clinic
trial
includ
patient
underli
malign
diseas
metaanalysi
mix
popul
critic
ill
patient
fail
show
benefit
intensifi
insulin
therapi
result
contrast
result
initi
trial
van
den
bergh
et
al
suggest
benefit
tight
blood
glucos
control
blood
glucos
level
mmoll
mgdl
thu
recommend
intens
insulin
therapi
aim
blood
glucos
level
mmoll
mgdl
ei
base
data
intern
guidelin
recommend
maintain
blood
glucos
level
least
mmoll
mgdl
biii
high
variabl
blood
glucos
level
septic
patient
avoid
associ
increas
mortal
biii
random
control
trial
metaanalys
report
increas
overal
mortal
increas
mortal
secondari
infect
nonneutropen
patient
sepsi
receiv
highdos
steroid
thu
highdos
corticosteroid
recommend
treatment
sepsi
ei
substitut
dose
hydrocortison
sepsi
remain
controversi
annan
et
al
identifi
benefit
mortal
treatment
group
corticu
trial
reveal
differ
mortal
treatment
placebo
found
higher
incid
hyperglycaemia
hypernatraemia
secondari
infect
treatment
group
result
metaanalys
similarli
contradictori
metaanalys
support
use
low
dose
hydrocortison
other
support
use
low
dose
hydrocortison
newer
data
three
observ
studi
total
patient
sepsi
registri
show
mortal
benefit
lowdos
steroid
thu
recommend
routin
use
substitut
dose
hydrocortison
neutropen
patient
sepsi
di
howev
lowdos
corticoid
treatment
may
consid
patient
insuffici
restor
blood
pressur
level
despit
adequ
fluid
resuscit
vasopressor
treatment
bii
result
three
ongo
larg
random
control
trial
hope
clarifi
role
lowdos
steroid
sever
sepsi
retrospect
trial
patient
sepsi
shown
reduct
mortal
use
unfraction
heparin
prospect
random
control
hetras
studi
investig
treatment
lowdos
heparin
iuh
day
patient
sepsi
influenc
allcaus
mortal
found
trial
character
low
mortal
perhap
explain
liber
inclus
criteria
treatment
discontinu
partial
thromboplastin
time
exceed
condit
administr
lowdos
heparin
safe
trial
includ
patient
defin
subgroup
need
recommend
use
heparin
neutropen
sepsi
made
ci
antithrombin
antithrombot
antiinflammatori
properti
base
neg
data
kybersept
trial
cochran
analysi
subgroup
analys
sever
trial
recommend
routin
use
antithrombin
treatment
neutropen
sepsi
absenc
dissemin
intravascular
coagul
dic
di
howev
patient
dic
sepsi
administr
antithrombin
may
consid
bii
respons
result
prowessshock
trial
apc
longer
use
thrombomodulin
decreas
thrombu
format
activ
protein
c
antiinflammatori
properti
result
phase
iib
studi
suggest
efficaci
patient
sepsi
suspect
dic
howev
safeti
efficaci
known
cytopen
patient
evidencebas
recommend
made
central
role
cytokin
hyper
antiinflammatori
phase
sepsi
prompt
clinic
studi
use
cytokin
cytokin
inhibitor
therapeut
agent
howev
studi
therapeut
efficaci
receptor
antagonist
tnfinhibitor
inhibitor
interferon
gamma
show
clinic
benefit
ei
known
effect
gcsf
gmcsf
increas
number
circul
granulocyt
rational
clinic
studi
assess
role
addit
therapi
antibiot
febril
patient
chemotherapyinduc
neutropenia
metaanalysi
random
control
trial
includ
total
patient
show
gcsfgmcsf
effect
reduc
time
neutrophil
recoveri
length
hospit
howev
despit
margin
signific
benefit
use
gcsfgmcsf
reduc
infectionrel
mortal
overal
mortal
appear
influenc
even
though
metaanalysi
report
mild
side
effect
associ
gcsfgmcsf
treatment
bone
pain
joint
pain
fluelik
symptom
accumul
number
public
respiratori
deterior
ard
gcsfgmcsfinduc
neutropenia
recoveri
nonneutropen
patient
pneumonia
sepsi
gcsfgmcsf
appear
safe
ineffect
reduc
mortal
rate
complic
infect
basi
current
studi
report
recommend
routin
addit
use
gcsf
gmcsf
standard
treatment
sepsi
neutropenia
di
although
gmcsf
seem
abl
revers
sepsisinduc
immun
paralysi
current
avail
treatment
eu
treatment
sepsi
neutropenia
iv
immunoglobulin
ivig
show
signific
differ
surviv
random
control
trial
metaanalysi
trial
ivig
patient
sepsi
identifi
trial
elig
evalu
compar
placebo
intervent
use
polyclon
ivig
associ
surviv
benefit
rel
risk
number
need
treat
save
one
life
nine
interestingli
sever
ill
patient
receiv
treatment
day
receiv
gkg
seem
benefit
individu
trial
analyz
flaw
design
rather
small
perform
time
standard
care
septic
patient
differ
today
author
conclud
larg
random
control
trial
perform
three
addit
metaanalys
investig
use
ivig
sepsi
similar
outcom
conclus
moder
degre
evid
support
use
ivig
sepsi
bii
sever
case
report
phase
iii
studi
shown
efficaci
granulocyt
transfus
patient
infect
sever
neutropenia
includ
patient
invas
fungal
infect
howev
complic
report
well
eg
fatal
cmv
infect
alloimmun
transfusionrel
acut
lung
injuri
syndrom
recent
random
control
trial
publish
fail
show
benefici
effect
small
author
discuss
sever
problem
associ
design
trial
metaanalysi
use
granulocyt
transfus
neutropen
neonat
yield
equivoc
result
taken
togeth
time
recommend
given
use
granulocyt
transfus
outsid
clinic
trial
recommend
substitut
platelet
pack
red
blood
cell
neutropen
patient
appli
patient
develop
sepsi
well
howev
cutoff
substitut
often
set
higher
valu
platelet
instead
biii
random
trial
children
sepsi
show
differ
outcom
liber
gdl
restrict
gdl
trigger
erythrocyt
transfus
although
prospect
random
studi
avail
recommend
transfus
trigger
gdl
haemoglobin
level
optim
tissu
oxygen
consensu
insid
panel
expert
regard
strength
recommend
tabl
summar
treatment
recommend
given
agiho
